Difference in Neutropenia due to Administration Schedule of TAS-102.
Case Rep Oncol
; 10(1): 226-229, 2017.
Article
em En
| MEDLINE
| ID: mdl-28611635
ABSTRACT
TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article